Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of PF-07275315 in moderate-to-severe asthma
jRCT2031250163Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of tilrekimig in asthma (4 arms), sponsored by Pfizer. Primary endpoints: Change from baseline in pre-bronchodilator FEV1 at Week 12, Incidence of treatment-emergent adverse events, serious adverse events, and AEs/SAEs leading to treatment discontinuation and 3 more. Started Aug 2025; status: recruiting.
02
Drugs
tilrekimig
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2031250163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250163.